J
Jan Cerny
Researcher at University of Massachusetts Medical School
Publications - 189
Citations - 3804
Jan Cerny is an academic researcher from University of Massachusetts Medical School. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 30, co-authored 170 publications receiving 3181 citations. Previous affiliations of Jan Cerny include Charles University in Prague & Memorial Medical Center.
Papers
More filters
Journal ArticleDOI
T-cell engagement of dendritic cells rapidly rearranges MHC class II transport
Marianne Boes,Jan Cerny,Jan Cerny,Ramiro Massol,Marjolein Op den Brouw,Tom Kirchhausen,Jianzhu Chen,Hidde L. Ploegh +7 more
TL;DR: It is proposed that tubular endosomes extend intracellularly and polarize towards the interacting T cell, but only when antigen-laden dendritic cells encounter T cells of the appropriate specificity, and serves to facilitate the ensuing T-cell response.
Journal ArticleDOI
Sustained Small Interfering RNA-Mediated Human Immunodeficiency Virus Type 1 Inhibition in Primary Macrophages
Erwei Song,Sang-Kyung Lee,Derek M. Dykxhoorn,Carl D. Novina,Dong Zhang,Keith D. Crawford,Jan Cerny,Phillip A. Sharp,Judy Lieberman,N. Manjunath,Premlata Shankar +10 more
TL;DR: In this paper, the authors investigated if sustained siRNA-mediated silencing of human immunodeficiency virus type 1 (HIV-1) is possible in terminally differentiated macrophages, which constitute an important reservoir of HIV in vivo.
Journal ArticleDOI
The small chemical vacuolin-1 inhibits Ca2+-dependent lysosomal exocytosis but not cell resealing
Jan Cerny,Jan Cerny,Yan Feng,Anan Yu,Katsuya Miyake,Barbara Borgonovo,Judith Klumperman,Jacopo Meldolesi,Paul L. McNeil,Tomas Kirchhausen +9 more
TL;DR: It is suggested that lysosomes are dispensable for resealing after wounding because cells heal normally in the presence of vacuolin‐1, the most potent compound.
Journal ArticleDOI
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.
Leyuan Ma,Yi Shan,Robert Bai,Liting Xue,Christopher A. Eide,Jianhong Ou,Lihua Julie Zhu,Lloyd Hutchinson,Jan Cerny,Hanna Jean Khoury,Zhi Sheng,Brian J. Druker,Shaoguang Li,Michael R. Green +13 more
TL;DR: A large-scale RNA interference screen reveals a new mechanism of imatinib resistance in chronic myeloid leukemia that can be therapeutically targeted and demonstrates that a U.S. Food and Drug Administration–approved drug can overcome this resistance and kill leukemia stem cells without harming the nonmalignant precursors that give rise to normal blood cells.
Journal ArticleDOI
T Cells Induce Extended Class II MHC Compartments in Dendritic Cells in a Toll-Like Receptor-Dependent Manner
Marianne Boes,Nicolas Bertho,Jan Cerny,Jan Cerny,Marjolein Op den Brouw,Tomas Kirchhausen,Hidde L. Ploegh +6 more
TL;DR: A Toll-like receptor-dependent signal is required to allow Ag-loaded dendritic cells to respond to T cell contact by formation of extended endosomal compartments, which does not result in massive translocation of class II MHC molecules to the cell surface.